...diseases. Stockwell is a professor at Columbia University and co-founder of Kyras Therapeutics Inc. and CombinatoRx...

...In April, Livzon Mabpharm led Epirus' $36 million series B round. Epirus subsequently reverse-merged with Zalicus Inc....

...In April, Livzon led Epirus' $36 million series B round. Epirus subsequently reverse-merged with Zalicus Inc....

...Horizon said its CombinatoRx division received a contract from Otsuka to perform in vitro cell line...
...completed” this year. The company declined to comment on specific research plans, but said the CombinatoRx...
...declined to comment on the deal. Horizon acquired its CombinatoRx division earlier this year from Zalicus Inc....

...Business: Cancer, Inflammation Hired: Justin Renz as EVP and CFO, formerly EVP and CFO of Zalicus Inc....

...Epirus (formerly Zalicus Inc. ) granted CRO AnaBios exclusive, worldwide rights to develop and commercialize the biotech’s...
...PN3 ; SCN10A ) sodium channels and are in preclinical testing to treat pain. Zalicus...
...sales of products resulting from the license. Earlier this month, Epirus completed a reverse-merger with Zalicus...

...Epirus completed its reverse merger with Zalicus, and the combined company, named Epirus Biopharmaceuticals Inc., began...
...began trading on NASDAQ under the ticker “EPRS” (see BioCentury, April 21 & July 14). Zalicus Inc....

...Zalicus said it and Epirus agreed that Zalicus shareholders will own 19% of the combined company...
...following completion of the companies’ merger. In April, the companies said Epirus would reverse-merge with Zalicus...
...companies have approved the deal, which is subject to approval by shareholders of both companies. Zalicus...

...candidate in three to four months. Margaret Lee, VP of research and translational medicine at Zalicus Inc....
...penetration per se, but that penetration to particular neurons is important," she said. Last week, Zalicus...
...of products resulting from the license. Zalicus EVP and CFO Justin Renz told BioCentury that Zalicus...

...Horizon completed its acquisition of Zalicus' CombinatoRx combination high throughput screening (cHTS) business and related assets...
...named Horizon CombinatoRx Inc. (see BioCentury, June 2). Horizon Discovery Group plc (LSE:HZD), Cambridge, U.K. Zalicus Inc....